Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Breast Neoplasms 1296 Carcinoma, Non-Small-Cell Lung 793 Neoplasms 787 Colorectal Neoplasms 760 Stomach Neoplasms 587 Carcinoma, Hepatocellular 581 Prostatic Neoplasms 514 Lung Neoplasms 466 Pancreatic Neoplasms 421 Rectal Neoplasms 336 Recurrence 314 Neoplasm Metastasis 308 Leukemia, Myeloid, Acute 293 Colonic Neoplasms 283 Multiple Myeloma 280 Lymphoma 276 Esophageal Neoplasms 273 Uterine Cervical Neoplasms 272 Ovarian Neoplasms 263 Melanoma 246 Head and Neck Neoplasms 245 Precursor Cell Lymphoblastic Leukemia-Lymphoma 210 Brain Neoplasms 195 Lymphoma, Large B-Cell, Diffuse 187 Nasopharyngeal Carcinoma 182 Leukemia 173 Lymphoma, Non-Hodgkin 171 Liver Neoplasms 165 Glioblastoma 160 Polycystic Ovary Syndrome 157

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Interventional × Fruquintinib × Clear all

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Unknown

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡